HAGH

Across TCGA pan-cancer cohorts, HAGH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HAGH data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HAGH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HAGH expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where HAGH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.637	0.287	.002	36	view →
CCRCC	OS	Quartile	All	1.000	0.851	.011	28	view →
LUAD	OS	Median	All	0.884	0.999	.020	11	view →
LSCC	OS	Median	II,III,IV	0.608	0.885	.011	4	view →
UCEC	DFS	Median	All	0.934	1.000	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HAGH–PDAC (DFS)

Open the PDAC breakdown →